Caris MI Profile is an advanced tumor profiling test that analyzes DNA, RNA, and protein expression to guide precision oncology treatment.
Comprehensive Analysis: DNA, RNA, and IHC profiling in a single test
Actionable Insights: Identifies targeted therapies, immunotherapy options, and clinical trials
High Sensitivity: Detects all classes of molecular alterations (mutations, fusions, amplifications, splice variants)
Clinical Utility: Helps oncologists tailor treatment plans based on tumor biology
Guideline-Based: Incorporates biomarkers referenced in NCCN and ESMO guidelines
Caris MI Profile provides a full molecular characterization of solid tumors using advanced sequencing technologies.
It analyzes more than 700 DNA genes, 20,000 RNA transcripts, and dozens of proteins using immunohistochemistry (IHC).
The goal is to match patients with the most effective therapies based on the genetic and molecular features of their tumor.
Tumor sample is submitted (from biopsy or surgical resection)
DNA and RNA sequencing + IHC and other biomarker testing
Results interpreted via AI-enhanced platform with expert review
Delivered to the treating physician with actionable recommendations
Patients with advanced, metastatic, or recurrent solid tumors
Individuals with rare cancers or tumors of unknown origin
Patients who have exhausted standard treatments and need guidance on next steps
Oncologists seeking data to support enrollment in clinical trials
